The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Adrenoleukodystrophy Treatment Market Research Report 2024
Synopsis
Market Analysis and Insights: Global Adrenoleukodystrophy Treatment Market
Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.
The global Adrenoleukodystrophy Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Oral Drugs accounting for % of the Adrenoleukodystrophy Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Adrenoleukodystrophy Treatment market size is valued at US$ million in 2021, while the North America and Europe Adrenoleukodystrophy Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Adrenoleukodystrophy Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenoleukodystrophy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenoleukodystrophy Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenoleukodystrophy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenoleukodystrophy Treatment market.
Global Adrenoleukodystrophy Treatment Scope and Market Size
Adrenoleukodystrophy Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Adrenoleukodystrophy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral Drugs
Parenteral Drugs
Segment by Application
Hospital
Clinic
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
bluebird bio
Orpheris
MedDay Pharmaceuticals
MINORYX THERAPEUTICS SL
Pfizer
Amgen
AstraZeneca
Abbott
agtc
ReceptoPharm
The Myelin Project
SOM Biotech
Viking Therapeutics
Nutra Pharma Corporation
Genetix Biotech
Magenta Therapeutics
NeuroVia
Novartis
CELGENE CORPORATION
Jazz Pharmaceuticals
Sanofi
Market Analysis and Insights: Global Adrenoleukodystrophy Treatment Market
Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.
The global Adrenoleukodystrophy Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Oral Drugs accounting for % of the Adrenoleukodystrophy Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Adrenoleukodystrophy Treatment market size is valued at US$ million in 2021, while the North America and Europe Adrenoleukodystrophy Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Adrenoleukodystrophy Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenoleukodystrophy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenoleukodystrophy Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenoleukodystrophy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenoleukodystrophy Treatment market.
Global Adrenoleukodystrophy Treatment Scope and Market Size
Adrenoleukodystrophy Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Adrenoleukodystrophy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral Drugs
Parenteral Drugs
Segment by Application
Hospital
Clinic
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
bluebird bio
Orpheris
MedDay Pharmaceuticals
MINORYX THERAPEUTICS SL
Pfizer
Amgen
AstraZeneca
Abbott
agtc
ReceptoPharm
The Myelin Project
SOM Biotech
Viking Therapeutics
Nutra Pharma Corporation
Genetix Biotech
Magenta Therapeutics
NeuroVia
Novartis
CELGENE CORPORATION
Jazz Pharmaceuticals
Sanofi
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Oral Drugs
1.2.3 Parenteral Drugs
1.3 Market by Application
1.3.1 Global Adrenoleukodystrophy Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Adrenoleukodystrophy Treatment Market Perspective (2017-2028)
2.2 Adrenoleukodystrophy Treatment Growth Trends by Region
2.2.1 Adrenoleukodystrophy Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Adrenoleukodystrophy Treatment Historic Market Size by Region (2017-2022)
2.2.3 Adrenoleukodystrophy Treatment Forecasted Market Size by Region (2023-2028)
2.3 Adrenoleukodystrophy Treatment Market Dynamics
2.3.1 Adrenoleukodystrophy Treatment Industry Trends
2.3.2 Adrenoleukodystrophy Treatment Market Drivers
2.3.3 Adrenoleukodystrophy Treatment Market Challenges
2.3.4 Adrenoleukodystrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue
3.1.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue (2017-2022)
3.1.2 Global Adrenoleukodystrophy Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Adrenoleukodystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adrenoleukodystrophy Treatment Revenue
3.4 Global Adrenoleukodystrophy Treatment Market Concentration Ratio
3.4.1 Global Adrenoleukodystrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenoleukodystrophy Treatment Revenue in 2021
3.5 Adrenoleukodystrophy Treatment Key Players Head office and Area Served
3.6 Key Players Adrenoleukodystrophy Treatment Product Solution and Service
3.7 Date of Enter into Adrenoleukodystrophy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenoleukodystrophy Treatment Breakdown Data by Type
4.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Type (2017-2022)
4.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Type (2023-2028)
5 Adrenoleukodystrophy Treatment Breakdown Data by Application
5.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Application (2017-2022)
5.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Adrenoleukodystrophy Treatment Market Size (2017-2028)
6.2 North America Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
6.3 North America Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Adrenoleukodystrophy Treatment Market Size (2017-2028)
7.2 Europe Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
7.3 Europe Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size (2017-2028)
8.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Adrenoleukodystrophy Treatment Market Size (2017-2028)
9.2 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
9.3 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adrenoleukodystrophy Treatment Market Size (2017-2028)
10.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 bluebird bio
11.1.1 bluebird bio Company Detail
11.1.2 bluebird bio Business Overview
11.1.3 bluebird bio Adrenoleukodystrophy Treatment Introduction
11.1.4 bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.1.5 bluebird bio Recent Development
11.2 Orpheris
11.2.1 Orpheris Company Detail
11.2.2 Orpheris Business Overview
11.2.3 Orpheris Adrenoleukodystrophy Treatment Introduction
11.2.4 Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.2.5 Orpheris Recent Development
11.3 MedDay Pharmaceuticals
11.3.1 MedDay Pharmaceuticals Company Detail
11.3.2 MedDay Pharmaceuticals Business Overview
11.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.3.4 MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.3.5 MedDay Pharmaceuticals Recent Development
11.4 MINORYX THERAPEUTICS SL
11.4.1 MINORYX THERAPEUTICS SL Company Detail
11.4.2 MINORYX THERAPEUTICS SL Business Overview
11.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Introduction
11.4.4 MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.4.5 MINORYX THERAPEUTICS SL Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adrenoleukodystrophy Treatment Introduction
11.5.4 Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Adrenoleukodystrophy Treatment Introduction
11.6.4 Amgen Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.6.5 Amgen Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Adrenoleukodystrophy Treatment Introduction
11.7.4 AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.7.5 AstraZeneca Recent Development
11.8 Abbott
11.8.1 Abbott Company Detail
11.8.2 Abbott Business Overview
11.8.3 Abbott Adrenoleukodystrophy Treatment Introduction
11.8.4 Abbott Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.8.5 Abbott Recent Development
11.9 agtc
11.9.1 agtc Company Detail
11.9.2 agtc Business Overview
11.9.3 agtc Adrenoleukodystrophy Treatment Introduction
11.9.4 agtc Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.9.5 agtc Recent Development
11.10 ReceptoPharm
11.10.1 ReceptoPharm Company Detail
11.10.2 ReceptoPharm Business Overview
11.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Introduction
11.10.4 ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.10.5 ReceptoPharm Recent Development
11.11 The Myelin Project
11.11.1 The Myelin Project Company Detail
11.11.2 The Myelin Project Business Overview
11.11.3 The Myelin Project Adrenoleukodystrophy Treatment Introduction
11.11.4 The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.11.5 The Myelin Project Recent Development
11.12 SOM Biotech
11.12.1 SOM Biotech Company Detail
11.12.2 SOM Biotech Business Overview
11.12.3 SOM Biotech Adrenoleukodystrophy Treatment Introduction
11.12.4 SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.12.5 SOM Biotech Recent Development
11.13 Viking Therapeutics
11.13.1 Viking Therapeutics Company Detail
11.13.2 Viking Therapeutics Business Overview
11.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Introduction
11.13.4 Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.13.5 Viking Therapeutics Recent Development
11.14 Nutra Pharma Corporation
11.14.1 Nutra Pharma Corporation Company Detail
11.14.2 Nutra Pharma Corporation Business Overview
11.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Introduction
11.14.4 Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.14.5 Nutra Pharma Corporation Recent Development
11.15 Genetix Biotech
11.15.1 Genetix Biotech Company Detail
11.15.2 Genetix Biotech Business Overview
11.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Introduction
11.15.4 Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.15.5 Genetix Biotech Recent Development
11.16 Magenta Therapeutics
11.16.1 Magenta Therapeutics Company Detail
11.16.2 Magenta Therapeutics Business Overview
11.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Introduction
11.16.4 Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.16.5 Magenta Therapeutics Recent Development
11.17 NeuroVia
11.17.1 NeuroVia Company Detail
11.17.2 NeuroVia Business Overview
11.17.3 NeuroVia Adrenoleukodystrophy Treatment Introduction
11.17.4 NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.17.5 NeuroVia Recent Development
11.18 Novartis
11.18.1 Novartis Company Detail
11.18.2 Novartis Business Overview
11.18.3 Novartis Adrenoleukodystrophy Treatment Introduction
11.18.4 Novartis Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.18.5 Novartis Recent Development
11.19 CELGENE CORPORATION
11.19.1 CELGENE CORPORATION Company Detail
11.19.2 CELGENE CORPORATION Business Overview
11.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Introduction
11.19.4 CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.19.5 CELGENE CORPORATION Recent Development
11.20 Jazz Pharmaceuticals
11.20.1 Jazz Pharmaceuticals Company Detail
11.20.2 Jazz Pharmaceuticals Business Overview
11.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.20.4 Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.20.5 Jazz Pharmaceuticals Recent Development
11.21 Sanofi
11.21.1 Sanofi Company Detail
11.21.2 Sanofi Business Overview
11.21.3 Sanofi Adrenoleukodystrophy Treatment Introduction
11.21.4 Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.21.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Oral Drugs
Table 3. Key Players of Parenteral Drugs
Table 4. Global Adrenoleukodystrophy Treatment Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Adrenoleukodystrophy Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Adrenoleukodystrophy Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Adrenoleukodystrophy Treatment Market Share by Region (2017-2022)
Table 8. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Adrenoleukodystrophy Treatment Market Share by Region (2023-2028)
Table 10. Adrenoleukodystrophy Treatment Market Trends
Table 11. Adrenoleukodystrophy Treatment Market Drivers
Table 12. Adrenoleukodystrophy Treatment Market Challenges
Table 13. Adrenoleukodystrophy Treatment Market Restraints
Table 14. Global Adrenoleukodystrophy Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Adrenoleukodystrophy Treatment Market Share by Players (2017-2022)
Table 16. Global Top Adrenoleukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Treatment as of 2021)
Table 17. Ranking of Global Top Adrenoleukodystrophy Treatment Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Adrenoleukodystrophy Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Adrenoleukodystrophy Treatment Product Solution and Service
Table 21. Date of Enter into Adrenoleukodystrophy Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adrenoleukodystrophy Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Adrenoleukodystrophy Treatment Revenue Market Share by Type (2017-2022)
Table 25. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Adrenoleukodystrophy Treatment Revenue Market Share by Type (2023-2028)
Table 27. Global Adrenoleukodystrophy Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Adrenoleukodystrophy Treatment Revenue Market Share by Application (2017-2022)
Table 29. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Adrenoleukodystrophy Treatment Revenue Market Share by Application (2023-2028)
Table 31. North America Adrenoleukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 32. North America Adrenoleukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 33. Europe Adrenoleukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 34. Europe Adrenoleukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 35. Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 36. Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 37. Latin America Adrenoleukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 38. Latin America Adrenoleukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 39. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 40. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 41. bluebird bio Company Detail
Table 42. bluebird bio Business Overview
Table 43. bluebird bio Adrenoleukodystrophy Treatment Product
Table 44. bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 45. bluebird bio Recent Development
Table 46. Orpheris Company Detail
Table 47. Orpheris Business Overview
Table 48. Orpheris Adrenoleukodystrophy Treatment Product
Table 49. Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 50. Orpheris Recent Development
Table 51. MedDay Pharmaceuticals Company Detail
Table 52. MedDay Pharmaceuticals Business Overview
Table 53. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product
Table 54. MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 55. MedDay Pharmaceuticals Recent Development
Table 56. MINORYX THERAPEUTICS SL Company Detail
Table 57. MINORYX THERAPEUTICS SL Business Overview
Table 58. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product
Table 59. MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 60. MINORYX THERAPEUTICS SL Recent Development
Table 61. Pfizer Company Detail
Table 62. Pfizer Business Overview
Table 63. Pfizer Adrenoleukodystrophy Treatment Product
Table 64. Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Amgen Company Detail
Table 67. Amgen Business Overview
Table 68. Amgen Adrenoleukodystrophy Treatment Product
Table 69. Amgen Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 70. Amgen Recent Development
Table 71. AstraZeneca Company Detail
Table 72. AstraZeneca Business Overview
Table 73. AstraZeneca Adrenoleukodystrophy Treatment Product
Table 74. AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 75. AstraZeneca Recent Development
Table 76. Abbott Company Detail
Table 77. Abbott Business Overview
Table 78. Abbott Adrenoleukodystrophy Treatment Product
Table 79. Abbott Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 80. Abbott Recent Development
Table 81. agtc Company Detail
Table 82. agtc Business Overview
Table 83. agtc Adrenoleukodystrophy Treatment Product
Table 84. agtc Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 85. agtc Recent Development
Table 86. ReceptoPharm Company Detail
Table 87. ReceptoPharm Business Overview
Table 88. ReceptoPharm Adrenoleukodystrophy Treatment Product
Table 89. ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 90. ReceptoPharm Recent Development
Table 91. The Myelin Project Company Detail
Table 92. The Myelin Project Business Overview
Table 93. The Myelin Project Adrenoleukodystrophy TreatmentProduct
Table 94. The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 95. The Myelin Project Recent Development
Table 96. SOM Biotech Company Detail
Table 97. SOM Biotech Business Overview
Table 98. SOM Biotech Adrenoleukodystrophy TreatmentProduct
Table 99. SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 100. SOM Biotech Recent Development
Table 101. Viking Therapeutics Company Detail
Table 102. Viking Therapeutics Business Overview
Table 103. Viking Therapeutics Adrenoleukodystrophy TreatmentProduct
Table 104. Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 105. Viking Therapeutics Recent Development
Table 106. Nutra Pharma Corporation Company Detail
Table 107. Nutra Pharma Corporation Business Overview
Table 108. Nutra Pharma Corporation Adrenoleukodystrophy TreatmentProduct
Table 109. Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 110. Nutra Pharma Corporation Recent Development
Table 111. Genetix Biotech Company Detail
Table 112. Genetix Biotech Business Overview
Table 113. Genetix Biotech Adrenoleukodystrophy TreatmentProduct
Table 114. Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 115. Genetix Biotech Recent Development
Table 116. Magenta Therapeutics Company Detail
Table 117. Magenta Therapeutics Business Overview
Table 118. Magenta Therapeutics Adrenoleukodystrophy TreatmentProduct
Table 119. Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 120. Magenta Therapeutics Recent Development
Table 121. NeuroVia Company Detail
Table 122. NeuroVia Business Overview
Table 123. NeuroVia Adrenoleukodystrophy TreatmentProduct
Table 124. NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 125. NeuroVia Recent Development
Table 126. Novartis Company Detail
Table 127. Novartis Business Overview
Table 128. Novartis Adrenoleukodystrophy TreatmentProduct
Table 129. Novartis Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 130. Novartis Recent Development
Table 131. CELGENE CORPORATION Company Detail
Table 132. CELGENE CORPORATION Business Overview
Table 133. CELGENE CORPORATION Adrenoleukodystrophy TreatmentProduct
Table 134. CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 135. CELGENE CORPORATION Recent Development
Table 136. Jazz Pharmaceuticals Company Detail
Table 137. Jazz Pharmaceuticals Business Overview
Table 138. Jazz Pharmaceuticals Adrenoleukodystrophy TreatmentProduct
Table 139. Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 140. Jazz Pharmaceuticals Recent Development
Table 141. Sanofi Company Detail
Table 142. Sanofi Business Overview
Table 143. Sanofi Adrenoleukodystrophy TreatmentProduct
Table 144. Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million)
Table 145. Sanofi Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adrenoleukodystrophy Treatment Market Share by Type: 2021 VS 2028
Figure 2. Oral Drugs Features
Figure 3. Parenteral Drugs Features
Figure 4. Global Adrenoleukodystrophy Treatment Market Share by Application in 2021 & 2028
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Home Care Case Studies
Figure 8. Adrenoleukodystrophy Treatment Report Years Considered
Figure 9. Global Adrenoleukodystrophy Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Adrenoleukodystrophy Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Adrenoleukodystrophy Treatment Market Share by Region: 2021 VS 2028
Figure 12. Global Adrenoleukodystrophy Treatment Market Share by Players in 2021
Figure 13. Global Top Adrenoleukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Treatment as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Adrenoleukodystrophy Treatment Revenue in 2021
Figure 15. North America Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 16. North America Adrenoleukodystrophy Treatment Market Share by Country (2017-2028)
Figure 17. United States Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. Canada Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Europe Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Adrenoleukodystrophy Treatment Market Share by Country (2017-2028)
Figure 21. Germany Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. France Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. U.K. Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Italy Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Russia Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Nordic Countries Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Adrenoleukodystrophy Treatment Market Share by Region (2017-2028)
Figure 29. China Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Japan Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. South Korea Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Southeast Asia Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. India Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Australia Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Latin America Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Adrenoleukodystrophy Treatment Market Share by Country (2017-2028)
Figure 37. Mexico Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Brazil Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Middle East & Africa Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Adrenoleukodystrophy Treatment Market Share by Country (2017-2028)
Figure 41. Turkey Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Saudi Arabia Adrenoleukodystrophy Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. bluebird bio Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 44. Orpheris Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 45. MedDay Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 46. MINORYX THERAPEUTICS SL Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 47. Pfizer Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 48. Amgen Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 49. AstraZeneca Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 50. Abbott Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 51. agtc Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 52. ReceptoPharm Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 53. The Myelin Project Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 54. SOM Biotech Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 55. Viking Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 56. Nutra Pharma Corporation Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 57. Genetix Biotech Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 58. Magenta Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 59. NeuroVia Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 60. Novartis Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 61. CELGENE CORPORATION Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 62. Jazz Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 63. Sanofi Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
